Literature DB >> 16075055

Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure.

Ichiro Shiojima1, Kaori Sato, Yasuhiro Izumiya, Stephan Schiekofer, Masahiro Ito, Ronglih Liao, Wilson S Colucci, Kenneth Walsh.   

Abstract

Although increased external load initially induces cardiac hypertrophy with preserved contractility, sustained overload eventually leads to heart failure through poorly understood mechanisms. Here we describe a conditional transgenic system in mice characterized by the sequential development of adaptive cardiac hypertrophy with preserved contractility in the acute phase and dilated cardiomyopathy in the chronic phase following the induction of an activated Akt1 gene in the heart. Coronary angiogenesis was enhanced during the acute phase of adaptive cardiac growth but reduced as hearts underwent pathological remodeling. Enhanced angiogenesis in the acute phase was associated with mammalian target of rapamycin-dependent induction of myocardial VEGF and angiopoietin-2 expression. Inhibition of angiogenesis by a decoy VEGF receptor in the acute phase led to decreased capillary density, contractile dysfunction, and impaired cardiac growth. Thus, both heart size and cardiac function are angiogenesis dependent, and disruption of coordinated tissue growth and angiogenesis in the heart contributes to the progression from adaptive cardiac hypertrophy to heart failure.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075055      PMCID: PMC1180541          DOI: 10.1172/JCI24682

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  56 in total

Review 1.  Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer.

Authors:  Napoleone Ferrara; Kenneth J Hillan; Hans-Peter Gerber; William Novotny
Journal:  Nat Rev Drug Discov       Date:  2004-05       Impact factor: 84.694

2.  Nuclear targeting of Akt enhances kinase activity and survival of cardiomyocytes.

Authors:  Isao Shiraishi; Jaime Melendez; Youngkeun Ahn; Maryanne Skavdahl; Elizabeth Murphy; Sara Welch; Erik Schaefer; Kenneth Walsh; Anthony Rosenzweig; Daniele Torella; Daria Nurzynska; Jan Kajstura; Annarosa Leri; Piero Anversa; Mark A Sussman
Journal:  Circ Res       Date:  2004-02-26       Impact factor: 17.367

3.  Genentech discloses safety concerns over Avastin.

Authors:  Mark Ratner
Journal:  Nat Biotechnol       Date:  2004-10       Impact factor: 54.908

4.  Loaded wheel running and muscle adaptation in the mouse.

Authors:  John P Konhilas; Ulrika Widegren; David L Allen; Angelika C Paul; Allison Cleary; Leslie A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2005-02-25       Impact factor: 4.733

5.  The FOXO3a transcription factor regulates cardiac myocyte size downstream of AKT signaling.

Authors:  Carsten Skurk; Yasuhiro Izumiya; Henrike Maatz; Peter Razeghi; Ichiro Shiojima; Marco Sandri; Kaori Sato; Ling Zeng; Stephan Schiekofer; David Pimentel; Stewart Lecker; Heinrich Taegtmeyer; Alfred L Goldberg; Kenneth Walsh
Journal:  J Biol Chem       Date:  2005-03-21       Impact factor: 5.157

6.  Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study.

Authors:  D Levy; R J Garrison; D D Savage; W B Kannel; W P Castelli
Journal:  N Engl J Med       Date:  1990-05-31       Impact factor: 91.245

7.  Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Authors:  Benjamin J Wilkins; Yan-Shan Dai; Orlando F Bueno; Stephanie A Parsons; Jian Xu; David M Plank; Fred Jones; Thomas R Kimball; Jeffery D Molkentin
Journal:  Circ Res       Date:  2003-12-01       Impact factor: 17.367

8.  Sex modifies exercise and cardiac adaptation in mice.

Authors:  John P Konhilas; Alexander H Maass; Stephen W Luckey; Brian L Stauffer; Eric N Olson; Leslie A Leinwand
Journal:  Am J Physiol Heart Circ Physiol       Date:  2004-08-19       Impact factor: 4.733

9.  Deletion of ribosomal S6 kinases does not attenuate pathological, physiological, or insulin-like growth factor 1 receptor-phosphoinositide 3-kinase-induced cardiac hypertrophy.

Authors:  Julie R McMullen; Tetsuo Shioi; Li Zhang; Oleg Tarnavski; Megan C Sherwood; Adam L Dorfman; Sarah Longnus; Mario Pende; Kathleen A Martin; John Blenis; George Thomas; Seigo Izumo
Journal:  Mol Cell Biol       Date:  2004-07       Impact factor: 4.272

10.  Inhibition of mTOR signaling with rapamycin regresses established cardiac hypertrophy induced by pressure overload.

Authors:  Julie R McMullen; Megan C Sherwood; Oleg Tarnavski; Li Zhang; Adam L Dorfman; Tetsuo Shioi; Seigo Izumo
Journal:  Circulation       Date:  2004-06-07       Impact factor: 29.690

View more
  388 in total

1.  NADPH oxidase-4 mediates protection against chronic load-induced stress in mouse hearts by enhancing angiogenesis.

Authors:  Min Zhang; Alison C Brewer; Katrin Schröder; Celio X C Santos; David J Grieve; Minshu Wang; Narayana Anilkumar; Bin Yu; Xuebin Dong; Simon J Walker; Ralf P Brandes; Ajay M Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-04       Impact factor: 11.205

2.  Hematopoietic Akt2 deficiency attenuates the progression of atherosclerosis.

Authors:  Noemi Rotllan; Aránzazu Chamorro-Jorganes; Elisa Araldi; Amarylis C Wanschel; Binod Aryal; Juan F Aranda; Leigh Goedeke; Alessandro G Salerno; Cristina M Ramírez; William C Sessa; Yajaira Suárez; Carlos Fernández-Hernando
Journal:  FASEB J       Date:  2014-11-12       Impact factor: 5.191

Review 3.  Emerging roles of SIRT1 deacetylase in regulating cardiomyocyte survival and hypertrophy.

Authors:  Nagalingam R Sundaresan; Vinodkumar B Pillai; Mahesh P Gupta
Journal:  J Mol Cell Cardiol       Date:  2011-01-27       Impact factor: 5.000

4.  c-Myc is required for proper coronary vascular formation via cell- and gene-specific signaling.

Authors:  Colby A Souders; Stephanie L K Bowers; Indroneal Banerjee; John W Fuseler; Jennifer L Demieville; Troy A Baudino
Journal:  Arterioscler Thromb Vasc Biol       Date:  2012-03-08       Impact factor: 8.311

5.  Erythropoietin and ventricular remodelling: a VEGF-dependent neovascularity.

Authors:  Tariq Hamid; Sumanth D Prabhu
Journal:  Cardiovasc Res       Date:  2010-05-05       Impact factor: 10.787

6.  Androgen receptor counteracts Doxorubicin-induced cardiotoxicity in male mice.

Authors:  Yasumasa Ikeda; Ken-ichi Aihara; Masashi Akaike; Takashi Sato; Kazue Ishikawa; Takayuki Ise; Shusuke Yagi; Takashi Iwase; Yuka Ueda; Sumiko Yoshida; Hiroyuki Azuma; Kenneth Walsh; Toshiaki Tamaki; Shigeaki Kato; Toshio Matsumoto
Journal:  Mol Endocrinol       Date:  2010-05-25

7.  Network-based predictions of in vivo cardiac hypertrophy.

Authors:  Deborah U Frank; Matthew D Sutcliffe; Jeffrey J Saucerman
Journal:  J Mol Cell Cardiol       Date:  2018-07-17       Impact factor: 5.000

8.  Short-term akt activation in cardiac muscle cells improves contractile function in failing hearts.

Authors:  Ichiro Shiojima; Stephan Schiekofer; Jochen G Schneider; Kurt Belisle; Kaori Sato; Martin Andrassy; Gennaro Galasso; Kenneth Walsh
Journal:  Am J Pathol       Date:  2012-09-30       Impact factor: 4.307

9.  Tachycardia pacing induces myocardial neovascularization and mobilizes circulating endothelial progenitor cells partly via SDF-1 pathway in canines.

Authors:  Jingting Mai; Fei Wang; Qiong Qiu; Buzhou Tang; YongQing Lin; NianSang Luo; WoLiang Yuan; XiaoLong Wang; Qingcai Chen; JingFeng Wang; YangXin Chen
Journal:  Heart Vessels       Date:  2014-12-10       Impact factor: 2.037

Review 10.  Signaling mechanisms in thyroid hormone-induced cardiac hypertrophy.

Authors:  Kaie Ojamaa
Journal:  Vascul Pharmacol       Date:  2009-12-11       Impact factor: 5.773

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.